The Melanocortin Peptides: Comparing PT-141, Melanotan 1 and Melanotan 2
The melanocortin peptides are a family of research compounds that act on the same signalling system in the body, yet they are often discussed as if they were unrelated. PT-141, Melanotan 1 and Melanotan 2 all trace back to the melanocortin receptors, but each was characterised for a different research interest. This overview compares the three at the level of mechanism, receptor selectivity and the literature, strictly for laboratory and research context.
The melanocortin system in brief
Melanocortin peptides are derived from a precursor protein called pro-opiomelanocortin (POMC). They act on five G-protein-coupled receptors, MC1R through MC5R, that are distributed across skin, the adrenal cortex, the central nervous system and other tissues. MC1R is closely associated with pigmentation research, while MC3R and MC4R, concentrated in hypothalamic regions, appear in studies of energy balance and central signalling.
Because a single compound can bind several of these receptors with different affinities, the research profile of each melanocortin peptide is shaped less by what it does in isolation and more by which receptors it prefers.
Melanotan 2 (MT-2): the non-selective parent compound
Melanotan 2 is a synthetic cyclic analog developed in the 1980s as a broad melanocortin receptor agonist. In the literature it is described as relatively non-selective, interacting with MC1R, MC3R, MC4R and MC5R. Its MC1R activity is the reason it became a reference compound in pigmentation research, and its activity at other receptors is what later prompted investigation of more selective derivatives.
For a deeper single-compound summary, see our overview of Melanotan 2 (MT-2).
PT-141 (Bremelanotide): the selective derivative
PT-141, also called bremelanotide, is a cyclic heptapeptide that emerged directly from work on Melanotan 2. A lactam bridge constrains its three-dimensional shape so that it preferentially fits the MC3R and MC4R binding pockets, with comparatively reduced affinity for MC1R and negligible activity at MC2R. In mechanistic studies, MC4R activation is linked to Gs-protein coupling, cAMP elevation and downstream signalling pathways in central regions.
This shift in receptor selectivity is the key distinction between PT-141 and its parent compound. Our dedicated note on PT-141 (Bremelanotide) covers the receptor pharmacology in more detail.
Melanotan 1 (Afamelanotide): the pigmentation-focused analog
Melanotan 1, known in the literature as afamelanotide, is a linear analog of alpha-MSH studied largely for its MC1R activity. Compared with Melanotan 2, it is generally described as more selective toward the pigmentation-associated MC1R pathway and less broadly active across the other melanocortin receptors. See our overview of Melanotan 1 (Afamelanotide) for the compound-specific summary.
How the three compare
Read side by side, the pattern is one of increasing specificity. Melanotan 2 is the broad, non-selective parent. Melanotan 1 narrows toward MC1R and the pigmentation literature. PT-141 narrows in the other direction, toward MC3R and MC4R. Researchers select among them based on which receptor pathway a study is designed to probe, not on interchangeability.
The three are available as separate research items: MT-2 (Melanotan 2), Melanotan 1 and PT-141.
Handling and storage
Like most research peptides, these are supplied as lyophilized powder. In a research setting they are typically reconstituted with bacteriostatic water, following a documented method such as our step-by-step reconstitution guide. The freeze-dried vials are stored cold and protected from light, and concentration is worked out beforehand using a tool like our reconstitution calculator.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.